CARL ZEISS MEDITEC AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.07 USD | -4.72% |
|
-8.18% | -15.64% |
| 31/05 | Carl Zeiss Meditec just above annual low - JPMorgan skeptical | DP |
| 31/05 | JPMorgan puts Carl Zeiss Meditec on 'Negative Catalyst Watch' | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With a 2024 P/E ratio at 29.69 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 3.57 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.64% | 8.21B | - | ||
| +7.01% | 217B | B | ||
| +11.01% | 190B | B- | ||
| +19.20% | 143B | B- | ||
| +30.79% | 111B | A- | ||
| +1.48% | 64.59B | A- | ||
| +13.95% | 52.36B | B+ | ||
| -0.16% | 48.45B | B+ | ||
| -6.20% | 38.03B | A | ||
| +0.91% | 35.6B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AFX Stock
- CZMWY Stock
- Ratings Carl Zeiss Meditec AG
